[go: up one dir, main page]

WO2002087587A3 - Amines bicycliques fusionnees - Google Patents

Amines bicycliques fusionnees Download PDF

Info

Publication number
WO2002087587A3
WO2002087587A3 PCT/GB2002/002011 GB0202011W WO02087587A3 WO 2002087587 A3 WO2002087587 A3 WO 2002087587A3 GB 0202011 W GB0202011 W GB 0202011W WO 02087587 A3 WO02087587 A3 WO 02087587A3
Authority
WO
WIPO (PCT)
Prior art keywords
aminosulfonylquinazolines
quinolines
tyrosine kinase
kinase inhibitors
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/002011
Other languages
English (en)
Other versions
WO2002087587A2 (fr
Inventor
David Festus Charles Moffat
Mark James Batchellor
Daniel Christopher Brookings
Peter David Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Priority to AU2002253350A priority Critical patent/AU2002253350A1/en
Publication of WO2002087587A2 publication Critical patent/WO2002087587A2/fr
Publication of WO2002087587A3 publication Critical patent/WO2002087587A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à des composés représentés par la formule (I) dans laquelle Ar est un groupe aryle, hétéroaryle, aralkyle, hétéroaralkyle ou alkyle éventuellement substitué, X est un atome d'azote ou un groupe C(R1a), n est égal à 0, 1 ou 2 et R, R?1, R2, R3, R4¿ sont des substituants définis dans la description. Ces composés son capables d'inhiber les tyrosine kinases réceptrices de classe 1 et s'avèrent utiles pour le traitement des troubles hyperprolifératifs tels que le psoriasis.
PCT/GB2002/002011 2001-05-02 2002-05-02 Amines bicycliques fusionnees Ceased WO2002087587A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002253350A AU2002253350A1 (en) 2001-05-02 2002-05-02 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0110797.8 2001-05-02
GBGB0110797.8A GB0110797D0 (en) 2001-05-02 2001-05-02 Chemical compounds

Publications (2)

Publication Number Publication Date
WO2002087587A2 WO2002087587A2 (fr) 2002-11-07
WO2002087587A3 true WO2002087587A3 (fr) 2003-01-09

Family

ID=9913913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/002011 Ceased WO2002087587A2 (fr) 2001-05-02 2002-05-02 Amines bicycliques fusionnees

Country Status (3)

Country Link
AU (1) AU2002253350A1 (fr)
GB (1) GB0110797D0 (fr)
WO (1) WO2002087587A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43098E1 (en) 2000-11-01 2012-01-10 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223689B2 (en) * 2002-04-12 2009-08-20 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
DE102007042154A1 (de) * 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
AU2009249106A1 (en) * 2008-05-21 2009-11-26 Genentech, Inc. Arylsulfonamide compounds, compositions and methods of use
CN106317037A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN106432215A (zh) * 2016-08-09 2017-02-22 浙江医药高等专科学校 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2473931A (en) * 1945-11-09 1949-06-21 Merck & Co Inc 2-and 4-sulfanilamido quinazoline
GB1092737A (en) * 1965-06-02 1967-11-29 Mead Johnson & Co 2-methoxy-4-[n-glutarylsulfanilamido]quinazoline and process for preparing the same
GB1144022A (en) * 1965-03-11 1969-03-05 Biochemie Gmbh Improvements in or relating to organic compounds
WO1996009294A1 (fr) * 1994-09-19 1996-03-28 The Wellcome Foundation Limited Composes heteroaromatiques substitues et leur utilisation en medecine
WO1997032856A1 (fr) * 1996-03-05 1997-09-12 Zeneca Limited Derives de 4-anilinoquinazoline
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO2001072720A1 (fr) * 2000-03-29 2001-10-04 Celltech Chiroscience Limited Derives d'amine bicyclique utilises comme inhibiteurs des tyrosines kinases receptrices de classe 1

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2473931A (en) * 1945-11-09 1949-06-21 Merck & Co Inc 2-and 4-sulfanilamido quinazoline
GB1144022A (en) * 1965-03-11 1969-03-05 Biochemie Gmbh Improvements in or relating to organic compounds
GB1092737A (en) * 1965-06-02 1967-11-29 Mead Johnson & Co 2-methoxy-4-[n-glutarylsulfanilamido]quinazoline and process for preparing the same
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1996009294A1 (fr) * 1994-09-19 1996-03-28 The Wellcome Foundation Limited Composes heteroaromatiques substitues et leur utilisation en medecine
WO1997032856A1 (fr) * 1996-03-05 1997-09-12 Zeneca Limited Derives de 4-anilinoquinazoline
WO2001072720A1 (fr) * 2000-03-29 2001-10-04 Celltech Chiroscience Limited Derives d'amine bicyclique utilises comme inhibiteurs des tyrosines kinases receptrices de classe 1

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002214204, Database accession no. 312115 (BRN) *
MARTIN, T. A. ET AL: "Sulfanilamidoquinazolines", JOURNAL OF MEDICINAL CHEMISTRY, vol. 7, 1964, pages 812 - 814, XP002214203 *
ZH. OBSHCH. KHIM.;, vol. 14, 1944, pages 848 - 854 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43098E1 (en) 2000-11-01 2012-01-10 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof

Also Published As

Publication number Publication date
AU2002253350A1 (en) 2002-11-11
WO2002087587A2 (fr) 2002-11-07
GB0110797D0 (en) 2001-06-27

Similar Documents

Publication Publication Date Title
MY147761A (en) Chemical compounds
EP1288202A4 (fr) Derives n-acyltetrahydroisoquinoline
HK1046687A1 (zh) 喹唑啉衍生物
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
PL1635835T3 (pl) Pochodne 2-aminopirymidyny jako inhibitory kinazy RAF
ATE321038T1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
PL368739A1 (en) Acetylene derivatives having mglur 5 antagonistic activity
AU2003248978A1 (en) Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
GEP20074198B (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials
WO2004014913A3 (fr) Inhibiteurs de la phosphodiesterase 4
WO2005092858A3 (fr) Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1
CA2309551A1 (fr) Inhibiteurs aminothiazoles de kinases dependantes de la cycline
WO2004098528A3 (fr) Composes de pyrazole-amines utiles en tant qu'inhibiteurs de kinases
WO2004005281A8 (fr) Inhibiteurs de tyrosine kinases
MXPA05006920A (es) Compuestos de quinazolina.
WO2001077107A8 (fr) Production et utilisation de composes heterocycliques
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
WO2004031401A3 (fr) Nouveaux inhibiteurs de tyrosine kinases
TW200505852A (en) Novel compounds
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
AU2001235838A1 (en) Imidazol derivatives as raf kinase inhibitors
WO2002074726A3 (fr) Inhibiteurs de phosphodiesterase 4
AU2003246100A1 (en) Amide derivative
GB0308201D0 (en) Novel compounds
WO2002062767A1 (fr) Nouveaux derives de quinazoline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP